Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for G-CSF Biosimilars in US$ by the following Product Segments: Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
Company profiles are primarily based on public domain information including company
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Pfizer
Novartis
Roche
In 2019, the market size of G-CSF Biosimilars is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for G-CSF Biosimilars.
This report studies the global market size of G-CSF Biosimilars, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the G-CSF Biosimilars sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Market Segment by Product Type
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Market Segment by Application
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the G-CSF Biosimilars status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key G-CSF Biosimilars manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of G-CSF Biosimilars are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Summary:
Get latest Market Research Reports on G-CSF Biosimilars. Industry analysis & Market Report on G-CSF Biosimilars is a syndicated market report, published as Global (United States, European Union and China) G-CSF Biosimilars Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of G-CSF Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.